[The gastric anti-ulcer effects of urogastrone, mainly attributable to its paralytic action on the hypothalamic centers regulating gastric secretion and motility].
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004597:Electroshock; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000378:metabolism*; D005768:Gastrointestinal Hormones / Q000627:therapeutic use*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007031:Hypothalamus / Q000187:drug effects*; D007275:Injections, Intravenous; D007328:Insulin / Q000494:pharmacology; D051381:Rats; D012636:Secretory Rate; D013276:Stomach Ulcer / Q000517:prevention & control*
D001786:Blood Glucose; D005768:Gastrointestinal Hormones; D007328:Insulin; D004815:Epidermal Growth Factor
Les effets antiulcereux gastriques de l'urogastrone, principalement attribuables a son action paralysante sur les centres hypothalamiques regulateurs de la secretion et de la motilite gastrique